News from Atom Therapeutics
23 June, 2026
PRESS RELEASE
Atom Therapeutics Announces First Patient Dosed in China Phase 3 Clinical Trial of Lingdolinurad...
15 June, 2026
PRESS RELEASE
Atom Therapeutics to Update Clinical Trials of Its Lead Drugs, a URAT1 Inhibitor for Chronic...
16 December, 2025
PRESS RELEASE
Atom Therapeutics Launches Multi-Regional Phase 2 Trial of ABP-745 for Atherosclerotic...
28 October, 2025
PRESS RELEASE
Atom Therapeutics Announces Partnering Opportunities For New Gout Therapies at BIO-Europe...
21 October, 2025
PRESS RELEASE
Atom Therapeutics to Present Positive Data from Clinical Trials of Its Lead Novel Oral...
15 September, 2025
PRESS RELEASE
Atom Therapeutics Enrolls First Patient in Multicenter Global Phase 2 Trial of...
07 September, 2025
PRESS RELEASE
Atom Therapeutics Announces Positive Topline Results of Lingdolinurad (ABP-671) in Phase...
01 July, 2025
PRESS RELEASE
Atom Therapeutics Names Dr. Min Fang as Clinical Vice President in China
ZHEJIANG, China...
22 May, 2025
PRESS RELEASE
Atom Therapeutics Joins Gout Education Society on Gout Awareness Day, May 22, to Help Educate...
03 December, 2024
PRESS RELEASE
Atom Therapeutics and China Medical System Holdings Enter Exclusive Commercialization Agreement...